Log in to your Inderes Free account to see all free content on this page.
Xvivo Perfusion
461
SEK
-0.54 %
XVIVO
NASDAQ Stockholm
Medical Equipment & Services
Health Care
Less than 1K followers
-0.54%
+3.6%
-5.73%
+3.13%
-11.35%
+67.94%
+90.5%
+177.38%
+2,326.32%
Xvivo Perfusion is a medical technology company. The company provides solutions for lung transplantation. Examples of products that the company delivers include needles, organ storage, and cooling solutions. The products are resold to clinics and research institutes around the global market, with the largest business presence in the Nordics and Europe. The company was established via a spin-off from Vitrolife in 2012 and is headquartered in Gothenburg.
Read moreMarket cap
14.52B SEK
Turnover
13.28M SEK
Revenue
EBIT %
P/E
Dividend yield-%
Financial calendar
24.4.
2025
Interim report Q1'25
25.4.
2025
General meeting '25
11.7.
2025
Interim report Q2'25
ShowingAll content types

XVIVO, Audiocast with teleconference, Q4'24
Year-end report 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Modular Finance IR Consensus: XVIVO Perfusion – Consensus estimates Q4 2024
Conference call on Year-end Report 2024
Enrollment completed five months early in the US clinical trial evaluating XVIVO’s heart preservation technology
XVIVO Perfusion appoints Lena Hagman as deputy CEO
Redeye: XVIVO Update - Excellent organic growth and a negative currency surprise

XVIVO, Audiocast with teleconference, Q3'24
Interim report January-September 2024
Modular Finance IR Consensus: XVIVO Perfusion – Consensus estimates Q3 2024
Conference call on Interim Report
XVIVO to acquire a unique communication platform for the transplant process
Nomination Committee of XVIVO Perfusion AB (publ)
Results from European randomized controlled study using XVIVO’s heart technology published in The Lancet
Redeye: XVIVO Q2 Update - Another roaring quarter
